Zentalis Pharmaceuticals, Inc. (ZNTL)

Zentalis Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	30.72	45.7	62.58	56.27	67.49
Short-Term Investments	454.88	394.3	280.17	283.55	0
Cash & Cash Equivalents	485.6	440	342.76	339.83	67.49
Cash Growth	10.36%	28.37%	0.86%	403.53%	168.30%
Receivables	0	0	0	0.42	0.14
Other Current Assets	11.12	11.94	8.01	4.86	1.26
Total Current Assets	496.72	451.93	350.77	345.1	68.89
Property, Plant & Equipment	41.74	50.08	52.84	3.62	2.84
Long-Term Investments	0	21.21	37.5	0	0
Goodwill and Intangibles	3.74	3.74	3.74	3.74	3.74
Other Long-Term Assets	9.5	12.35	9.67	13.1	12.02
Total Long-Term Assets	54.97	87.38	103.74	20.45	18.59
Total Assets	551.69	539.31	454.51	365.56	87.48
Accounts Payable	14.93	11.25	11.59	8.66	4.29
Other Current Liabilities	54.44	45.4	32.35	19.94	10.61
Total Current Liabilities	69.37	56.65	43.94	28.6	14.9
Long-Term Debt	43.15	45.17	44.46	1.1	0
Other Long-Term Liabilities	1.78	3.47	1.62	2.48	4.16
Total Long-Term Liabilities	44.93	48.64	46.08	3.58	4.16
Total Liabilities	114.3	105.29	90.03	32.18	19.06
Total Debt	43.15	45.17	44.46	1.1	0
Debt Growth	-4.46%	1.59%	3952.78%	-	-
Retained Earnings	-888.56	-596.37	-359.56	-200.83	-82.99
Comprehensive Income	2.19	-1.35	-0.13	0.04	0
Shareholders' Equity	437.28	433.8	363.95	308.58	-80.11
Net Cash / Debt	442.45	394.83	298.3	338.73	67.49
Net Cash / Debt Growth	12.06%	32.36%	-11.94%	401.90%	168.30%
Net Cash Per Share	6.76	7.47	6.99	12.05	12.06
Working Capital	427.35	395.29	306.83	316.5	53.99
Book Value Per Share	6.68	8.21	8.53	10.98	-14.31

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).